Pfizer secures European approval for Xeljanz to treat ulcerative colitis

This article was originally published here

The marketing authorization has been granted for Xeljanz10 mg twice-daily (BID) for at least eight weeks, followed by Xeljanz 5mg BID or 10 mg BID, to treat adult

The post Pfizer secures European approval for Xeljanz to treat ulcerative colitis appeared first on Pharma Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply